

transplantation in a 12-year-old patient with severe combined immunodeficiency. *N. Engl. J. Med.*, 312(18): 1151-1159, 1985.

62. Levine, A.M. Lymphoma complicating immunodeficiency disorders. *Ann. Oncology*, 5: s29-s35, 1994.

63. Purtilo, D.T., Tatsumi, E., Manolov, G., Manolova, Y., Harada, S., Lipscomb, H., and Krueger, G. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aplastic diseases in immune deficient patients. *Int. Rev. Exp. Path.*, 27: 113-183, 1985.

64. Kagami, Y., Nakamura, S., Suzuki, R., Yatabe, Y., Okada, Y., Kobayashi, T., Taniwaki, M., Seto, M., Ogura, M., and Suchi, T. A nodal gamma/d T-cell lymphoma with an association of Epstein-Barr virus. *Am. J. Surg. Pathol.*, 21: 729-736, 1997.

65. McKnight, J.L.C., Cen, H., Riddler, S.A., Breinig, M.C., Williams, P.A., Ho, M., and Joseph, P.S. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. *Leuk. Lymphoma*, 15: 9-16, 1994.

66. Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., Sands, J., Gottman, D., Katz, B.Z., and Sklar, J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. *N. Engl. J. Med.*, 318: 733-741, 1988.

67. Su, L.-J., Hsieh, H.-C., Lin, K.-H., Uen, W.-C., Kao, C.-L., Chen, C.-J., Cheng, A.-L., Kadin, M.E., and Chen, J.-Y. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysis. *Blood*, 77: 799-808, 1991.

68. Purtilo, D.T. Epstein-barr-virus-induced oncogenesis in immune-deficient individuals. *Lancet*, 300-303, 1980.

69. Joske, D. and Knecht, H. Epstein-Barr virus in lymphomas: A review. *Blood Rev.*, 7: 215-222, 1993.

70. Purtilo, D.T. and Stevenson, M. Lymphotropic viruses as etiologic agents of lymphoma. *Hematology/Oncology Clinics of North America*, 5: 901-923, 1991.

71. De Vita, S., Sacco, C., Sansonno, D., Gloghini, A., Dammaco, F., Crovatto, M., Santini, G., Dolcetti, R., Boiocchi, M., Carbone, A., and Zagonel, V. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. *Blood*, 90: 776-782, 1997.

72. Zuckerman, E., Zuckerman, T., Levin, A.M., Douer, D., Gutekunst, K., Mizokami, M., Qian, D.G., Velankar, M., Nathwani, B.N., and Fong, T.-L. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. *Ann. Intern. Med.*, 127: 423-428, 1997.

73. Ferri, C., La Civita, L., Monti, M., Giannini, C., Cecchetti, R., Caracciolo, F., Longombardo, G., Lombardini, F., and Zignego, A.L. Chronic hepatitis C and B-cell non-Hodgkin's lymphoma. *QJM*, 89: 117-122, 1996.

74. Silvestri, F., Barillari, G., Farin, R., Pipan, C., Falasca, E., Salmaso, F., Zaja, F., Infanti, L., Patriarca, F., and Botta, G.A. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. *Leukemia*, 11: 2157-2161, 1997.
75. Zignego, A.L., Macchia, D., Monti, M., Thiers, V., Mazzetti, M., Foschi, M., Maggi, E., Romagnani, S., Gentilini, P., and Brechot, C. Infection of peripheral mononuclear blood cells by hepatitis C virus. *Journal of hepatology*, 15: 382-386, 1992.
76. Lee, S.-H., Su, I.-J., Chen, R.-L., Lin, K.-S., Lin, D.-T., and Chuu, W.-M. A pathologic study of childhood lymphoma in Taiwan with special reference to peripheral T-cell lymphoma and the association with Epstein-Barr viral infection. *Cancer*, 68: 1954-1962, 1991.
77. Cammarota, G., Tursi, A., Mantalto, M., Papa, A., Branca, G., Vecchio, F.M., Renzi, C., Verzi, A., Annuzzi, A., Pretolani, S., Fedeli, G., and Gasbarrini, G. Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-*H. Pylori* therapy. *J. Clin. Gastroenterol*, 21: 118-122, 1995.
78. Bayerdorffer, E., Neubauer, A., Rudolph, B., Thiede, C., Lehn, N., Eidt, S., and Stolte, M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of *Helicobacter pylori* infection. *Lancet*, 345: 1591-1594, 1995.
79. Doglioni, C., Wotherspoon, A.C., Moschini, A., De Boni, M., and Isaacson, P.G. High incidence of primary gastric lymphoma in northeastern Italy. *Lancet*, 339: 834-835, 1992.
80. Eck, M., Schmauber, B., Haas, R., Greiner, A., Czub, S., and Muller-Hermelink, H.K. MALT-type lymphoma of the stomach is associated with *Helicobacter pylori* strains expressing the CagA protein. *Gastroenterology*, 112: 1482-1486, 1997.
81. Forman, D., Sitas, F., Newell, D.G., Stacey, A.R., Boreham, J., Peto, R., Campbell, T.C., Li, J., and Chen, J. Geographic association of *Helicobacter pylori* antibody prevalence and gastric cancer mortality in rural China. *Int. J. Cancer*, 46: 608-611, 1990.
82. Walt, R.P. Regression of MALT lymphoma and treatment for *Helicobacter pylori*. *Lancet*, 348: 1041-1042, 1996.
83. Tatham, L., Tolbert, P., and Kjeldsberg, C. Occupational risk factors for subgroups of non-Hodgkin's lymphoma. *Epidemiology*, 8: 551-558, 1997.
84. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., De Wolf-Peters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.-K., Pileri, S.A., Piris, M.A., Ralfkiaer, E., and Warnke, R.A. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. *Blood*, 84: 1361-1392, 1994.

85. Jaffe, E.S., Harris, N.L., Diebold, J., and Muller-Hermelink, H.K. World Health Organization classification of lymphomas: A work in progress. *Ann. Oncol.*, 9 Suppl: S25-S30, 1998.
86. Koepfen, H. and Vardiman, J.W. New entities, issues, and controversies in the classification of malignant lymphoma. *Semin. Oncol.*, 25: 421-434, 1998.
87. Harrington, D.S., Ye, Y., Weisenburger, D.D., Armitage, J.O., Pierson, J., Bast, M., and Purtilo, D.T. Malignant lymphoma in Nebraska and Guangzhou, China. *Hum. Pathol.*, 18: 924-928, 1987.
88. Ko, Y.-H., Kim, C.-W., Park, C.-S., Jang, H.-K., Lee, S.-S., Ree, H.-J., Lee, J.-D., and Kim, S.-W. REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. *Cancer*, 83: 806-811, 1998.
89. Intratumorachai, T., Wannakraij, P., Chaimongkol, B., Bhoopat, L., Lekhakula, A., Thamprasit, T., Suwanwela, N., Suthipintha Wong, C., Prayoonwiwat, W., Meekungwal, P., Sirijerachai, C., and Pairojkul, C. Non-Hodgkin's lymphomas in Thailand: A retrospective pathologic and clinical analysis of 1391 cases. *Cancer*, 78: 1813-1812, 1996.
90. Yang, K. A histopathologic and immunopathologic study of 209 malignant lymphoma casgions of China: Suzhou, Nanjing, Qingdao and Shenyang. *Chung Hua Chung Liu Tsa Chih*, 15: 86-90, 1993.
91. Klein, G. and Klein, E. Sinking surveillance's flagship. *Nature*, 395: 441-444, 1998.
92. Nilsson, K. and Klein, G. Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. *Adv. Cancer Res.*, 37: 319-380, 1982.
93. Chang, K.L. and Weiss, L.M. The association of the Epstein-Barr virus with malignant lymphoma. *Biomed. Pharmacother.*, 50: 459-467, 1996.
94. Chan, J.K.C., Tsang, W.Y.W., Ng, C.S., Wong, C.S.C., and Lo, E.S.F. A study of the association of Epstein-Barr virus with Burkitt's lymphoma occurring in a Chinese population. *Histopathology*, 26: 239-245, 1995.
95. Quintanilla-Martinez, L., Lome-Maldonado, C., Ott, G., Gschwendtner, A., Gredler, E., Reyes, E., Angeles-Angeles, A., and Fend, F. Primary non-Hodgkin's lymphoma of the intestine: High prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. *Blood*, 89: 644-651, 1997.
96. Wolvius, E.B., Jiwa, N.M., van der Valk, P., Horstman, A., and van der Waal, E. Adenolymphoma and non-Hodgkin's lymphoma of the salivary glands and oral cavity in immunocompetent patients are not associated with latent Epstein-Barr virus. *Oral Oncology*, 33: 119-123, 1997.

97. Elenitoba, K.S.J., Zarate-Osorno, A., Meneses, A., Krenacs, L., Kingma, D.W., Raffeld, M., and Jaffe, E.S. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. *Mod. Pathol.*, 11: 754-761, 1998.
98. Ohsawa, M., Nakatsuka, S.-I., Kanno, H., Miwa, H., Kojima, S., Harabuchi, Y., Yang, W.-I., and Aozasa, K. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. *Int. J. Cancer*, 81: 865-870, 1999.
99. Wu, S.-J., Lay, J.-D., Chen, C.-L., Chen, J.-Y., Liu, M.-Y., and Su, I.-J. Genomic analysis of Epstein-Barr virus in nasal and peripheral T-cell lymphoma: A comparison with nasopharyngeal carcinoma in an endemic area. *J Med Virol*, 50: 314-321, 1996.
100. Huh, J., Cho, K., Heo, D.S., Kim, J.E., and Kim, C.W. Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. *Am. J. Hematol.*, 60: 205-214, 1999.
101. Chan, J.K.C., Yip, T.T.C., Tsang, W.Y.W., Ng, C.S., Lau, W.H., Poon, Y.F., Wong, C.C.S., and Ma, Y.W.S. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. *Am. J. Surg. Pathol.*, 18: 938-946, 1994.
102. Ho, F.C.S., Srivastava, G., Loke, S.L., Fu, K.H., Leung, B.P.Y., Liang, R., and Choy, D. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and T cell type. *Hematol. Oncol.*, 8: 271-281, 1990.
103. Harabuchi, Y., Imai, S., Wakashima, J., Hirao, M., Kataura, A., Osato, T., and Kon, S. Nasal T-cell lymphoma causally associated with Epstein-Barr virus. *Cancer*, 77: 2137-2149, 1996.
104. Cheng, A.-L., Su, I.-J., Chen, Y.-C., Uen, W.-C., and Wang, C.-H. Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. *Cancer*, 72: 909-916, 1993.
105. Zhou, X.G., Hamilton-Dutoit, S.J., Yan, Q.H., and Pallesen, G. High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma. *Histopathology*, 24: 115-122, 1994.
106. Abdel-Hamid, M., Chen, J.-J., Constantine, N., Massoud, M., and Raab-Traub, N. EBV strain variation: Geographical distribution and relation to disease state. *Virology*, 190: 168-175, 1992.
107. Lung, M.L., Chang, R.S., Huang, M.L., Guo, H.-Y., Choy, D., Sham, J., Tsao, S.-Y., Cheng, P., and Ng, M.N. Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in Southern China. *Virology*, 177: 44-53, 1990.

108. Chen, X., Pepper, S.de V., and Arrand, J.R. Prevalence of the A and B types of Epstein-Barr virus DNA in nasopharyngeal carcinoma biopsies from southern China. *J Gen Virol*, 73: 463-466, 1992.
109. Yuan, J.-M., Govindarajan, S., Henderson, B.E., and Yu, M.C. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. *Br. J. Cancer*, 74: 491-493, 1996.
110. Wu, R.-R., Mizokami, M., Cao, K., Nakano, T., Ge, X.-M., Wang, S.-S., Orito, E., Ohba, K.-I., Mukaide, M., Hikiji, K., Lau, J.Y.N., and Iino, S. GB virus C/hepatitis G virus infection in southern China. *Journal of Infectious Diseases*, 175: 168-171, 1997.
111. Suzuki, K., Mizokami, M., Cao, K., Wu, X.-S., Wu, R.-R., Hata, A., Sasaki, M., Fang, Z.-X., Zhang, L.-Y., Lau, J.Y.N., and Iino, S. Prevalence of hepatitis C virus infection in Nanjing, Southern China. *European Journal of Epidemiology*, 13: 511-515, 1997.
112. McColl, M.D., Singer, I.O., Tati, R.C., McNeil, I.R.R., Cumming, R.L.C., and Hogg, R.B. The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma-A regional association? *Leuk. Lymphoma*, 26: 127-130, 1997.
113. Mazzaro, C., Zagonel, V., Monfardini, S., Tulissi, P., Pussini, E., Fanni, M., Sorio, R., Bortolus, R., Crovatto, M., Santini, G., Tribelli, C., Sasso, F., Masutti, R., and Pozzato, G. Hepatitis C virus and non-Hodgkin's lymphomas. *Br. J. Haematol.*, 94: 544-550, 1996.
114. Ohsawa, M., Shingu, N., Miwa, H., Yoshihara, H., Kubo, M., Tsukuma, H., Teshima, H., Hashimoto, M., and Aozasa, K. Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. *Int. J. Cancer*, 80: 237-239, 1999.
115. Vallisa, D., Berte, R., Rocca, A., Civardi, G., Giangregorio, F., Ferrari, B., Sbolli, G., and Cavanna, L. Association between hepatitis C virus and Non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. *Am. J. Med.*, 106: 556-560, 1999.
116. Alvaro, T., Bosch, R., Salvado, M.T., and Piris, M.A. True histiocytic lymphoma of the stomach associated with low-grade B-cell mucosa-associated lymphoid tissue (Malt)-type lymphoma. *Am. J. Surg. Pathol.*, 20: 1406-1411, 1996.
117. Cammarota, G., Tursi, A., Montalto, M., Papa, A., Veneto, G., Trua, F., Addolorato, G., Verzi, A., Certo, M., Cuoco, L., Branca, G., Fedeli, G., and Gasbarrini, G. Clinical assessment of the relationship of *Helicobacter pylori* to gastroduodenal pathologies. *Panminerva Med.*, 37: 178-181, 1995.
118. Cammarota, G., Tursi, A., Papa, A., Voso, M.T., Serra, F., Chiusolo, P., Fedeli, G., and Gasbarrini, G. The growth of primary low-grade B-cell gastric lymphoma is sustained by *Helicobacter pylori*. *Scand. J. Gastroenterol*, 32: 285-287, 1997.

119. Carlson, S.J., Yokoo, H., and Vanagunas, A. Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of *Helicobacter pylori*. JAMA, 275: 937-939, 1996.
120. Chan, J.K.C. Gastrointestinal lymphomas: An overview with emphasis on new findings and diagnostic problems. Semin. Diagn. Pathol., 13: 260-296, 1996.
121. Solcia, E., Fiocca, R., Luinetti, O., Villani, L., Padovan, L., Calistri, D., Ranzani, G.N., Chiaravalli, A., and Capella, C. Intestinal and diffuse gastric cancers arise in a different background of *Helicobacter pylori* gastritis through different gene involvement. Am. J. Surg. Pathol., 20: S8-S22, 1996.
122. Martin, J., Boyle, S., and Jacyna, M. Regression of a large gastric MALT lymphoma with antibiotic treatment to eradicate *Helicobacter pylori*. Postgrad. Med. J., 73: 109-110, 1997.
123. Vanagunas, A. Eradication of *Helicobacter pylori* and regression of B-cell lymphoma. Biomed. Pharmacother., 51: 156-160, 1997.
124. IARC Monographs on the Evaluation of carcinogenic risks to humans: Infection with *Helicobacter pylori*. IARC, 61: 177-241, 1994.
125. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. p53 mutations in human cancers. Science, 253: 49-53, 1991.
126. Harris, C.C. 1995 Deichmann Lecture-p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol Lett, 82-83: 1-7, 1995.
127. Kleihues, P., Aguzzi, A., and Ohgaki, H. Genetic and environmental factors in the etiology of human brain tumors. Toxicol. Lett., 82-83: 601-605, 1995.
128. Lo Coco, F., Gaidano, G., Louie, D.C., Offit, K., Chaganti, R.S.K., and Dalla-Favera, R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82: 2289-2295, 1993.
129. Bhatia, K., Goldschmidt, W., Gutierrez, M., Gaidano, G., Dalla-Favera, R., and Magrath, I. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J., 7: 951-956, 1993.
130. Oka, T., Sarker, A.B., Teramoto, N., Yoshino, T., and Akagi, T. p53 protein expression in non-Hodgkin's lymphomas is infrequently related to p53 gene mutations. Pathology International, 48: 15-21, 1998.
131. Clodi, K., Younes, A., Goodacre, A., Roberts, M., Palmer, J., Younes, M., Cabanillas, F., and Andreeff, M. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence *in-situ* hybridization. Br. J. Haematol., 98: 913-921, 1997.

132. Chen, P.-M., Chiou, T.-J., Hsieh, R.-K., Fan, F.S., Chu, C.-J., Lin, C.-Z., Chiang, H., Yen, C.-C., Wang, W.-S., and Liu, J.-H. p53 gene mutations and rearrangements in non-Hodgkin's lymphoma. *Cancer*, 85: 718-724, 1999.
133. Koduru, P.R.K., Raju, K., Vadmal, V., Menezes, G., Shah, S., Susin, M., Kolitz, J., and Broome, J.D. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. *Blood*, 90: 4078-4091, 1997.
134. Moller, M.B., Ino, Y., Gerdes, A.-M., Skjodt, K., Louis, D.N., and Pedersen, N.T. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. *Leukemia*, 13: 453-459, 1999.
135. Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E., and Maiolo, A.T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. *Blood*, 81: 128-135, 1993.
136. Freudhomme, C., Facon, T., Zandecki, M., Vanrumbeke, M., Lai, J.L., Nataf, E., Loucheux-Lefebvre, M.H., Kerckaert, J.P., and Fenaux, P. Rare occurrence of p53 gene mutations in multiple myeloma. *Br. J. Haematol.*, 81: 440-443, 1992.
137. Yasuga, Y., Hirose, S., Yamamoto, K., Tomiyama, J., Nagata, K., and Aokia, N. N-ras and p53 gene mutations are very rare events in multiple myeloma. *International Journal of Hematology*, 62: 91-97, 1995.
138. Wada, M., Betram, C.R., Nakamura, H., Hachiya, M., Chen, D.-L., Borenstein, J., Miller, C.W., Ludwig, L., Hansen-Hagge, T.E., Ludwig, W.-D., Reiter, A., Mizoguchi, H., and Koefler, H.P. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. *Blood*, 82: 3163-3169, 1993.
139. Kipen, H.M., Cody, R.P., Crump, K.S., Allen, B.C., and Goldstein, B.D. Hematologic effects of benzene: a thirty-five year longitudinal study of rubber workers. *Toxicol Ind Health*, 4(4): 411-430, 1988.
140. Momose, H., Jaffe, E.S., Shin, S.S., Chen, Y.-Y., and Weiss, L.M. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. *Am. J. Surg. Pathol.*, 16: 859-867, 1992.
141. Tsai, S.P., Wen, C.P., Weiss, N.S., Wong, O., McClellan, W.A., and Gibson, R.L. Retrospective Mortality and Medical Surveillance Studies of Workers in Benzene Areas of Refineries. *J. Occup. Med.*, 25(9): 685-692, 1983.
142. Rothman, N., Li, G.-L., Dosemeci, M., Bechtold, W.E., Marti, G.E., Wang, Y.-Z., Linet, M., Xi, L., Lu, W., Smith, M.T., Titenko-Holland, N., Zhang, L.-P., Blot, W., Yin, S.-N., and Hayes, R.B. Hematotoxicity among Chinese workers heavily exposed to benzene. *Am. J. Ind. Med.*, 29: 236-246, 1996.

143. Rothman, N., Smith, M.T., Hayes, R.B., Li, G.L., Irons, R.D., Dosemeci, M., Haas, R., Stillman, W.S., Linet, M., Xi, L.Q., Bechtold, W.E., Wiemels, J., Campleman, S., Zhang, L.P., Quintana, P.J.E., Titenko-Holland, N., Wang, Y.Z., Lu, W., Kolachana, P., Meyer, K.B., and Yin, S.N. An epidemiologic study of early biologic effects of benzene in Chinese workers. *Environ. Health Perspect.*, 104 Suppl. 6: 1365-1370, 1996.

144. Zhang, L.P., Rothman, N., Wang, Y.X., Hayes, R.B., Bechtold, W., Venkatesh, P., Yin, S.N., Wang, Y.Z., Dosemeci, M., Li, G.L., Lu, W., and Smith, M.T. Interphase cytogenetics of workers exposed to benzene. *Environ. Health Perspect.*, 104 Suppl. 6: 1325-1329, 1996.

145. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., and Sultan, C. Proposals for the classification of the myelodysplastic syndromes. *Br. J. Haematol.*, 51: 189-199, 1982.

146. Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J., Sawitsky, A., Stass, S., Weinstein, H., and Woods, W.G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. *J. Clin. Oncol.*, 8: 813-819, 1990.

147. Bennett, J.M., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., and Sultan, C. Proposals for the classification of the acute leukaemias. *Br. J. Haematol.*, 33: 451-458, 1976.

148. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., and Sultan, C. Proposed revised criteria for the classification of acute myeloid leukemia. *Ann. Intern. Med.*, 103: 626-629, 1985.

149. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders: Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. *Cancer Genet. Cytogenet.*, 32: 1-10, 1988.

150. Bennett, J.M. Secondary acute myeloid leukemia. *Leuk. Res.*, 19: 231-232, 1995.

151. Vardiman, J.W., Coelho, A., Golomb, H.M., and Rowley, J. Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. *Am. J. Clin. Pathol.*, 525-530, 1983.

152. Orazi, A., Cattoretti, G., Soligo, D., Luksch, R., and Lambertenghi-Deliliers, G. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology of the prognostic assessment. *Leukemia*, 7: 838-847, 1993.

153. Estey, E.H., Keating, M.J., Dixon, D.O., Trujillo, J.M., McCredie, K.B., and Freireich, E.J. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. *Hematol. Pathol.*, 1: 203-208, 1987.

-
154. Bain, B.J. *Leukaemia Diagnosis*. p. 1. Malden: Blackwell Science, 1999.
155. Pugh, W.C., Pearson, M.N., Vardiman, J.W., and Rowley, J.D. Philadelphia Chromosome-Negative Chronic Myelogenous Leukaemia: A Morphological Reassessment. *Br. J. Haematol.*, 60: 457-467, 1985.
156. Van Lom, K., Hagemeijer, A., Vandekerckhove, F., De Greef, G.E., Sacchi, N., and Löwenberg, B. Clonality analysis of hematopoietic cell lineages in acute myeloid leukemia and translocation (8;21): Only myeloid cells are part of the malignant clone. *Leukemia*, 11: 202-205, 1997.
157. Hussey, C.E., Lyon, E., Millson, A., Lay, M.J., Wittwer, C.T., and Segal, G.H. A rapid practical RT-PCR-based approach for the detection of the PML/RARalpha fusion transcript in acute promyelocytic leukemia. *Am. J. Clin. Pathol.*, 112: 256-262, 1999.
158. Secker-Walker, L.M., Moorman, A.V., Bain, B.J., and Mehta, A.B. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. *Leukemia*, 12: 840-844, 1998.
159. Poirel, H., Rack, K., Delabesse, E., Radford-Weiss, I., Troussard, X., Debert, C., Leboeuf, D., Bastard, C., Picard, F., Veil-Buzyn, A., Flandrin, G., Bernard, O., and Macintyre, E. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. *Blood*, 87: 2496-2505, 1996.
160. Raab-Traub, N. and Flynn, K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. *Cell*, 47: 883-889, 1986.
161. Moore, P.S., Kingsley, L.A., Holmberg, S.D., Spira, T., Gupta, P., Hoover, D.R., Parry, J.P., Conley, L.J., Jaffe, H.W., and Chang, Y. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. *AIDS*, 10: 175-180, 1996.
162. Sawada, K., Sato, N., Notoya, A., Tarumi, T., Hirayama, S., Takano, H., Koizumi, K., Yasukouchi, T., Yamaguchi, M., and Koike, T. Proliferation and differentiation of myelodysplastic CD34⁺ cells: Phenotypic subpopulations of marrow CD34⁺ cells. *Blood*, 85: 194-202, 1995.
163. Tjonnfjord, G.E., Steen, R., Veiby, O.P., and Egeland, T. Lineage commitment of CD34⁺ human hematopoietic progenitor cells. *Exp. Hematol.*, 24: 875-882, 1996.
164. Siegel, D., McGuinness, S.M., Wiski, S.L., and Ross, D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. *Pharmacogenetics*, 9: 113-121, 1999.

165. Traver, R.D., Siegel, D., Beall, H.D., Phillips, R.M., Gibson, N.W., Franklin, W.A., and Ross, D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). *Br. J. Cancer*, 75: 69-75, 1997.
166. Rothman, N., Smith, M.T., Hayes, R.B., Traver, R.D., Hoener, B.A., Campleman, S., Li, G.L., Dosemeci, M., Linet, M., Zhang, L.P., Xi, L.Q., Wacholder, S., Lu, W., Meyer, K.B., Titenko-Holland, N., Stewart, J.T., Yin, S.N., and Ross, D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the *NQO1* 609C→T mutation and rapid fractional excretion of chlorzoxazone. *Cancer Res.*, 57: 2839-2842, 1997.
167. Larson, R.A., Wang, Y.X., Banerjee, M., Wiemels, J., Hartford, C., Le Beau, M.M., and Smith, M.T. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (*NQO1*) gene in patients with primary and therapy-related myeloid leukemia. *Blood*, 94: 803-807, 1999.
168. Marin, A., Lopez de Cerain, A., Hamilton, E., Lewis, A.D., Martinez-Penuela, J.M., Idoate, M.A., and Bello, J. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. *Br. J. Cancer*, 76: 923-929, 1997.
169. Kelsey, K.T., Ross, D., Traver, R.D., Christiani, D.C., Zuo, Z.-F., Spitz, M.R., Wang, M., Xu, X., Lee, B.-K., Schwartz, B.S., and Wiencke, J.K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. *Br. J. Cancer*, 76: 852-854, 1997.
170. Schattenberg, D.G., Stillman, W.S., Gruntmeir, J.J., Helm, K.M., Irons, R.D., and Ross, D. Peroxidase activity in murine and human hematopoietic progenitor cells. Potential relevance to benzene-induced toxicity. *Mol. Pharmacol.*, 46: 346-351, 1994.
171. Eastmond, D.A., Smith, M.T., and Irons, R.D. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. *Toxicol. Appl. Pharmacol.*, 91: 85-95, 1987.
172. Ross, D., Siegel, D., Schattenberg, D.G., Sun, X.M.M., and Moran, J.L. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: Identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. *Environ. Health Perspect.*, 104 Suppl. 6: 1177-1182, 1996.
173. Ross, D. Metabolic basis of benzene toxicity. *Eur. J. Haematol.*, 57 Suppl. 60: 111-118, 1996.
174. London, S.J., Lehman, T.A., and Taylor, J.A. Myeloperoxidase genetic polymorphism and lung cancer risk. *Cancer Res.*, 57: 5001-5003, 1997.

175. Stillman, W.S., Varella-Garcia, M., and Irons, R.D. The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and-5q31 in a human cell line. *Leuk. Lymphoma*, 35: 269-281, 1999.
176. Stillman, W.S., Varella-Garcia, M., Gruntnieir, J.J., and Irons, R.D. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line. *Leukemia*, 11: 1540-1545, 1997.
177. Stillman, W.S., Varella-Garcia, M., and Irons, R.D. The benzene metabolite, hydroquinone, selectively induces 5q31- and -7 in human CD34+CD19- bone marrow cells. *Exp. Hematol.*, 1999.(in press)
178. Ohshima, K., Suzumiya, J, Sato, K. et al. B cell lymphoma: 708 cases in Japan: incident rates and clinical prognosis according to the REAL classification. *Cancer Lett.* 135: 73-81, 1999.
179. Inoue, O. et. al. Quantitative relation of urinary phenoles to breathzone benzene concentrations: a factory survey. *Br. J. Ind. Med.* 43: 692-697, 1986.
180. Collins, J.J., Conner, P. et al. A study of the hematologic effects of chronic low level exposure to benzene. *J. Occup. Med.* 33: Suppl 5, 619-625, 1991.